WealthTrust Fairport’s Celldex Therapeutics CLDX Stock Holding History

WealthTrust Fairport’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-7	Closed	-$2K	–	182
2014 Q4	$2K	Hold	7	–	–	﹤0.01%	414
2014 Q3	$1K	Hold	7	–	–	﹤0.01%	337
2014 Q2	$2K	Buy	+7	New	+$1.58K	﹤0.01%	299

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WealthTrust Fairport's CLDX Position: Q1 2015 in Review

WealthTrust Fairport sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 7 shares — an estimated $2K sold.

WealthTrust Fairport first reported a position in CLDX in Q2 2014 and held it in 3 quarters. The position peaked at $2K in Q4 2014. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

WealthTrust Fairport reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
WealthTrust Fairport sold 7 Celldex Therapeutics shares in Q1 2015, an estimated $2K.
WealthTrust Fairport first reported a position in Celldex Therapeutics in Q2 2014 and held it in 3 quarters.
WealthTrust Fairport's Celldex Therapeutics position peaked at $2K in Q4 2014.
193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on WealthTrust Fairport's 13F filing for Q1 2015, filed 14 May 2015.